QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 0.80579
-- x --
-- x --
-- - --
$ 0.40 - $ 3.51
1,985
na
2.21M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2023 09-30-2023 10-Q
2 08-11-2023 06-30-2023 10-Q
3 05-12-2023 03-31-2023 10-Q
4 03-31-2023 12-31-2022 10-K
5 11-10-2022 09-30-2022 10-Q
6 08-12-2022 06-30-2022 10-Q
7 05-06-2022 03-31-2022 10-Q
8 03-30-2022 12-31-2021 10-K
9 11-08-2021 09-30-2021 10-Q
10 08-16-2021 06-30-2021 10-Q
11 05-07-2021 03-31-2021 10-Q
12 03-12-2021 12-31-2020 10-K
13 11-06-2020 09-30-2020 10-Q
14 08-07-2020 06-30-2020 10-Q
15 05-08-2020 03-31-2020 10-Q
16 03-06-2020 12-31-2019 10-K
17 11-06-2019 09-30-2019 10-Q
18 08-07-2019 06-30-2019 10-Q
19 05-09-2019 03-31-2019 10-Q
20 03-14-2019 12-31-2018 10-K
21 11-08-2018 09-30-2018 10-Q
22 08-10-2018 06-30-2018 10-Q
23 05-10-2018 03-31-2018 10-Q
24 03-16-2018 12-31-2017 10-K
25 11-14-2017 09-30-2017 10-Q
26 10-13-2017 06-30-2017 10-K
27 05-22-2017 03-31-2017 10-Q
28 02-10-2017 12-31-2016 10-Q
29 11-14-2016 09-30-2016 10-Q
30 10-13-2016 06-30-2016 10-K
31 05-12-2016 03-31-2016 10-Q
32 02-16-2016 12-31-2015 10-Q
33 11-16-2015 09-30-2015 10-Q
34 10-09-2015 06-30-2015 10-K
35 05-14-2015 03-31-2015 10-Q
36 02-17-2015 12-31-2014 10-Q
37 11-14-2014 09-30-2014 10-Q
38 09-29-2014 06-30-2014 10-K
39 05-09-2014 03-31-2014 10-Q
40 02-14-2014 12-31-2013 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eloxx-pharmaceuticals-reports-additional-confirmation-that-all-nonsense-mutation-alport-syndrome-patients-treated-with-elx-02-in-phase-2-study-had-improvement-in-kidney-morphology-and-clinical-benefit-of-reduction-or-stabilization-of-proteinuria

ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney...

 eloxx-pharmaceuticals-announces-2m-registered-direct-offering-priced-at-the-market-under-nasdaq-rules

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announ...

 eloxx-pharmaceuticals-provides-program-updates-on-elx-02-and-zkn-013

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of...

 why-22nd-century-group-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into...

 eloxx-pharmaceuticals-q2-eps-196-misses-154-estimate

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(1.96) per share which missed the analyst consensus estimate ...

 why-us-steel-shares-are-trading-higher-by-23-here-are-20-stocks-moving-premarket

Gainers AGBA Group Holding Limited (NASDAQ: AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company repo...

 why-progressive-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-thursdays-mid-day-session

Gainers

 why-senmiao-technology-are-trading-higher-by-15-here-are-20-stocks-moving-premarket

Gainers Jiuzi Holdings, Inc. (NASDAQ: JZXN) shares surged 106.8% to $5.77 in pre-market trading. The stock began trading on ...

 why-lucid-group-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to preven...

 why-immucell-are-trading-higher-here-are-20-stocks-moving-premarket

Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION